t
Futura Medical plc will announce its interim results for the six months ended 30 June 2023 on Monday 18th September 2023. The Company will host a webcast for investors and analysts on that day. A Retail Investor event is scheduled for Tuesday 19th September at 10.00am BST.
| Date | 18 Aug 2023 |
| Time | 07:00:04 |
| Category | Results |
| ID | 6806J |
18 August 2023
Futura Medical plc
("Futura" or the "Company")
Notice of Interim Results
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products, will announce its interim results for the six months ended 30 June 2023 on Monday 18th September 2023.
The Company will host a webcast for investors and analysts on the day of the results, which will be made available within the investor centre section of the Company's website.
A Retail Investor event is scheduled for Tuesday 19th September at 10.00am BST with Investor Meet Company. Retail Investors can register via www.investormeetcompany.com.
-ENDS-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: [email protected]
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates
Email: [email protected]
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.
MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.
MED3000 is being manufactured and commercialised under the brand name Eroxon® in regulatory approved countries and is FDA approved in the US, CE marked in Europe and UKCA marked in the UK and a growing number of countries across the world. Futura has commercial agreements with the likes of Haleon for the US market and Cooper Consumer Health for Europe.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.